Pharmacotherapeutics for the treatment of methamphetamine addiction

The Problem

Our Mission

Methamphetamine (“meth”) is a highly addictive substance whose abuse entails terrible physical, psychological, and social consequences. Meth addiction is a serious public health crisis in the US.

According to data from the 2012 National Survey on Drug Use and Health (NSDUH), over 12 million people (4.7% of the US population) have tried methamphetamine at least once.The US spends an estimated $23 billion on meth-related expenses annually including medical treatment, lost quality of life, premature death, lab cleanup and explosions, crime and incarceration, child endangerment, and lost productivity.

Currently, there are no FDA-approved pharmacological treatments for methamphetamine abuse.

Quickbeam partners with the research, academic and clinical communities to identify and develop molecular therapies that directly counteract the biological and behavioral effects of chronic methamphetamine abuse, for the ultimate purpose of creating a pharmacological treatment for methamphetamine addiction.